OmniAb, Inc.
Devendra Srivastava has a wealth of experience in the field of protein sciences. Devendra currently holds the position of Director of Protein Sciences at OmniAb, Inc. since November 2022. Prior to that, they worked as the Director of Protein Sciences at Ligand Pharmaceuticals from November 2021 to October 2022. Before joining Ligand Pharmaceuticals, Devendra served as a Senior Scientist/Projects Lead at Denali Therapeutics, where they worked from 2019 to November 2021. Devendra also worked as a Scientist II at Atreca, Inc. from 2017 to 2019, and as a Principle Investigator/Scientist at Precision IBD, Inc. in 2016-2017. Devendra's career also includes positions as a Scientist at the New York Structural Biology Center from 2015 to 2016, an Instructor at the Icahn School of Medicine at Mount Sinai from 2013 to 2015, a Postdoctoral Researcher at Harvard Medical School from 2011 to 2013, and a Postdoctoral Associate at The Rockefeller University from 2008 to 2011.
Devendra Srivastava completed their Master of Science (MSc) degree in Biochemistry from Banaras Hindu University from 1999 to 2001. Devendra then went on to pursue a Doctor of Philosophy (PhD) degree in Biochemistry and Structural Biology from All India Institute of Medical Sciences from 2002 to 2007.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.